MLH1 and neoplasm: Within the diagnostic pathway, only 17.8% of patients with EC were recorded as having received functional MMR tumour testing, only 43.1% of eligible patients received MLH1 promoter hypermethylation testing and of patients with EC eligible from tumour-testing only 25% were recorded as having received a germline MMR gene test.